A Fosun Pharma subsidiary has paid Junshi Biosciences 215 million yuan ($32 million) for Chinese rights to a near-approval autoimmune disease drug candidate.
Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market
Post navigation
Previous Post
Food Web Complexity Drives Biodiversity Impact